Phenotypes associated with this allele

• Allele Symbol: Tg(Fabp7-cre,-lacZ)3Gtm
• Allele Name: transgene insertion 3, David H Gutmann
• Allele ID: MGI:3810647
• Summary: 9 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Phox2b^tm1Rth/Phox2b^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129 * C57BL/6 * CBA	MGI:7397265
cn2	Ctnnb1^tm1Mmt/Ctnnb1^+ Pik3ca^tm1Gilb/Pik3ca^+ Trp53^tm1Brn/Trp53^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA	MGI:5438217
cn3	Ctnnb1^tm1Mmt/Ctnnb1^+ Trp53^tm1Brn/Trp53^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA	MGI:5438218
cn4	Nf1^tm1Par/Nf1^tm1Par Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:3810648
cn5	Gt(ROSA)26Sor^tm1Fia/Gt(ROSA)26Sor^+ Nf1^tm1Par/Nf1^tm1Par Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:3810651
cn6	Tg(CAG-lacZ,-Akt1*,-EGFP)56Ebm/0 Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:3811010
cn7	Nf1^tm1Par/Nf1^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:3810649
cn8	Kras^tm4Tyj/Kras^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:3810650
cn9	Gt(ROSA)26Sor^tm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm/Gt(ROSA)26Sor^+ Tg(Fabp7-cre,-lacZ)3Gtm/0	involves: 129S6/SvEvTac * C57BL/6 * CBA	MGI:5543815

Genotype
MGI:7397265

cn1

• Allelic Composition: Phox2b^tm1Rth/Phox2b⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129 * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

abnormal suckling behavior ( J:331513 )

• pups fail to nurse and gain adequate body weight

respiratory system

decreased pulmonary respiratory rate ( J:331513 )

• mice show spontaneous/continuous breathing, albeit at a slightly reduced frequency, and do not exhibit cyanosis

nervous system

nervous system phenotype ( J:331513 )

N • mice show normal locus coeruleus tyrosine hydroxylase + populations and normal number of serotonergic neurons expressing tryptophan hydroxylase

abnormal retrotrapezoid nucleus morphology ( J:331513 )

• brainstems show loss of the retrotrapezoid nucleus

abnormal facial nerve morphology ( J:331513 )

• brainstems show loss of the seventh cranial nerve (CNVII) nuclei

• abnormal formation of CNVII in the embryonic brainstem is due to failure of precursor migration

Genotype
MGI:5438217

cn2

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Pik3ca^tm1Gilb/Pik3ca⁺; Trp53^tm1Brn/Trp53⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA

neoplasm

increased medulloblastoma incidence ( J:186709 )

• by 3 months of age, all mice develop WNT-subgroup medulloblastomas

nervous system

increased medulloblastoma incidence ( J:186709 )

• by 3 months of age, all mice develop WNT-subgroup medulloblastomas

Genotype
MGI:5438218

cn3

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Trp53^tm1Brn/Trp53⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA

neoplasm

increased medulloblastoma incidence ( J:186709 )

• by 11 months, 4% of mice develop WNT-subgroup medulloblastomas

nervous system

increased medulloblastoma incidence ( J:186709 )

• by 11 months, 4% of mice develop WNT-subgroup medulloblastomas

Genotype
MGI:3810648

cn4

• Allelic Composition: Nf1^tm1Par/Nf1^tm1Par; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

mortality/aging

premature death ( J:139866 )

• no mice survive beyond 3 months of age

postnatal lethality, incomplete penetrance ( J:139866 )

• the majority of pups fail to survive to weaning

• median survival is 18 days

nervous system

nervous system phenotype ( J:139866 )

N • brain weight is not significantly decreased and the major anatomical areas of the forebrain are not significantly different from controls

abnormal pituitary gland morphology ( J:138868 )

small adenohypophysis ( J:138868 )

• significantly smaller than control littermates

• however, the posterior lobe is similar in size to that in controls

abnormal pituitary gland development ( J:138868 )

• 3-fold reduction in proliferating cells in the anterior lobe of the pituitary gland

• no change in proliferation in the posterior lobe

small pituitary gland ( J:138868 )

abnormal brain development ( J:139866 )

• increases in the numbers of Olig2+ glial and BLBP+ neuroglial progenitors are seen throughout the brain

• expression analysis indicates abnormalities in development and differentiation of neocortical neurons

abnormal hippocampus morphology ( J:139866 )

• at 1 week of age, an increase in proliferating cells is seen in the CA2/3 region

• however, when normalized to the number of progenitor cellsno increase in the percentage of proliferating cells is detected

abnormal secondary somatosensory cortex morphology ( J:139866 )

• decrease in the distance between the corpus callosum and the brain surface in the secondary somatosensory cortex indicating a reduction in cortex thickness

• pre- and post-natal treatment with Rolipram restores normal somatosensory cortical thickness

abnormal CNS glial cell morphology ( J:139866 )

• increase in the number of NG2+ glial cells in the brain including the somatosensory cortex

abnormal astrocyte morphology ( J:139866 )

• increase in the number of GFAP+ astrocytes in the brain

• gene-dose dependent increase in the number of astrocytes in the CA1 region of the hippocampus

increased oligodendrocyte number ( J:139866 )

• increase in the number of APC+ oligodendroglial cells in the brain including the fimbria

abnormal dendrite morphology ( J:139866 )

• apical dendrites of layer II/III pyramidal neurons in the somatosensory cortex are shorter compared to littermate controls

• pre- and post-natal treatment with Rolipram partially restores neurite length

abnormal nervous system physiology ( J:139866 )

• decrease in intracellular cAMP levels in the brain

abnormal neuronal precursor proliferation ( J:139866 )

• increase in proliferation at E13.5 and to a lesser extent at E17.5 primarily in neuroglial progenitor cells

abnormal pituitary gland physiology ( J:138868 )

• significant reduction in growth hormone and prolactin mRNA levels

abnormal hypothalamus physiology ( J:138868 )

• 50% reduction in cAMP levels in hypothalamic homogenates

growth/size/body

decreased body weight ( J:138868 , J:139866 )

• greater than 60% reduction in body weight compared to controls by 3 weeks of age (J:138868)

• weigh about 30% of the weight of control littermates at 2 - 3 months of age (J:138868)

• Rolipram treatment increases body weight but mice are still smaller than controls (J:138868)

• at P18, weight is less than 50% that of control littermates (J:139866)

postnatal growth retardation ( J:138868 , J:139866 )

• severe growth retardation develops during the first week after birth (J:138868)

• develop progressive growth retardation from P3 (J:139866)

• all major organ systems, except the central nervous system, display growth retardation at P18 (J:139866)

endocrine/exocrine glands

abnormal pituitary gland morphology ( J:138868 )

small adenohypophysis ( J:138868 )

• significantly smaller than control littermates

• however, the posterior lobe is similar in size to that in controls

abnormal pituitary gland development ( J:138868 )

• 3-fold reduction in proliferating cells in the anterior lobe of the pituitary gland

• no change in proliferation in the posterior lobe

small pituitary gland ( J:138868 )

abnormal pituitary gland physiology ( J:138868 )

• significant reduction in growth hormone and prolactin mRNA levels

homeostasis/metabolism

abnormal hormone level ( J:138868 )

• decrease in growth hormone releasing hormone levels in the primary capillaries of the hypophyseal portal system

decreased circulating growth hormone level ( J:138868 )

• a 65% reduction in liver Igf1 mRNA levels indicates a reduction in circulating growth hormone levels

behavior/neurological

abnormal behavior ( J:139866 )

• extreme sensitivity to handling

abnormal voluntary movement ( J:139866 )

• limited range of movement of the hindlimbs

cellular

abnormal neuronal precursor proliferation ( J:139866 )

• increase in proliferation at E13.5 and to a lesser extent at E17.5 primarily in neuroglial progenitor cells

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
neurofibromatosis 1		DOID:0111253	OMIM:162200	J:138868

Genotype
MGI:3810651

cn5

• Allelic Composition: Gt(ROSA)26Sor^tm1Fia/Gt(ROSA)26Sor⁺; Nf1^tm1Par/Nf1^tm1Par; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

nervous system

small adenohypophysis ( J:138868 )

• significantly smaller than control littermates

growth/size/body

decreased body weight ( J:138868 )

endocrine/exocrine glands

small adenohypophysis ( J:138868 )

• significantly smaller than control littermates

homeostasis/metabolism

decreased circulating growth hormone level ( J:138868 )

• reduction in liver Igf1 mRNA levels indicates a reduction in circulating growth hormone levels

Genotype
MGI:3811010

cn6

• Allelic Composition: Tg(CAG-lacZ,-Akt1*,-EGFP)56Ebm/0; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

mortality/aging

mortality/aging ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , mice are viable with no reduction in life span

nervous system

nervous system phenotype ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm no change in pyramidal neuron apical dendrite length or neuritic development are detected

abnormal brain development ( J:139866 )

• increase in the number of Olig2+ progenitor cells

abnormal hippocampus morphology ( J:139866 )

• an increase in proliferating cells is seen in the CA2/3 region

abnormal CNS glial cell morphology ( J:139866 )

• expansion of glial cells similar to that in mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm

abnormal astrocyte morphology ( J:139866 )

• increase in the number of GFAP+ astrocytes in the brain

growth/size/body

growth/size/body region phenotype ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , no growth retardation is seen

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , no impairment in pituitary gland development is detected

Genotype
MGI:3810649

cn7

• Allelic Composition: Nf1^tm1Par/Nf1⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

nervous system

abnormal astrocyte morphology ( J:139866 )

• gene-dose dependent increase in the number of astrocytes in the CA1 region of the hippocampus

Genotype
MGI:3810650

cn8

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

mortality/aging

mortality/aging ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , mice are viable with no reduction in life span

nervous system

nervous system phenotype ( J:139866 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm no change in pyramidal neuron apical dendrite length or neuritic development are detected

abnormal brain development ( J:139866 )

• increase in the number of Olig2+ progenitor cells

abnormal hippocampus morphology ( J:139866 )

• an increase in proliferating cells is seen in the CA2/3 region

abnormal CNS glial cell morphology ( J:139866 )

• expansion of glial cells similar to that in mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm

abnormal astrocyte morphology ( J:139866 )

• increase in the number of GFAP+ astrocytes in the brain

growth/size/body

growth/size/body region phenotype ( J:138868 , J:139866 )

N (J:138868)

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , no growth retardation is seen (J:139866)

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:138868 )

N • unlike mice homozygous for Nf1^tm1Par and hemizygous for Tg(Fabp7-cre)2Gtm , no impairment in pituitary gland development is detected

Genotype
MGI:5543815

cn9

• Allelic Composition: Gt(ROSA)26Sor^{tm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm}/Gt(ROSA)26Sor⁺; Tg(Fabp7-cre,-lacZ)3Gtm/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * CBA

mortality/aging

premature death ( J:204469 )

• mice are born in Mendelian ratios but do not survive beyond 8 to 10 weeks

digestive/alimentary system

abnormal digestive system morphology ( J:204469 )

• abnormal alimentary canal, ranging from severely swollen stomachs to blackened hindguts

abnormal hindgut morphology ( J:204469 )

• blackened hindguts in some mice

enlarged stomach ( J:204469 )

• severely swollen in some mice

abnormal digestive system physiology ( J:204469 )

• mice become malnourished

nervous system

nervous system phenotype ( J:204469 )

N • cell proliferation and survival are normal in the cerebellum

increased astrocyte number ( J:204469 )

• GFAP+ and S100B+ without a change in proliferation or apoptosis rates